Immunomodulatory therapy for sepsis: An update
Opal, Steven M.
SourceExpert Review of Anti-Infective Therapy
Google Scholar check
MetadataShow full item record
Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis. © 2011 Expert Reviews Ltd.
Showing items related by title, author, creator and subject.
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Cutsem, E. Van; Dicato, M.; Arber, N.; Berlin, J.; Cervantes, A.; Ciardiello, F.; Gramont, A. De; Diaz-Rubio, E.; Ducreux, M.; Geva, R.; Glimelius, B.; Glynne-Jones, R.; Grothey, Axel; Gruenberger, T.; Haller, D.; Haustermans, K.; Labianca, R.; Lenz, H. J.; Minsky, B.; Nordlinger, B.; Ohtsu, A.; Pavlidis, Nicholas; Rougier, P.; Schmiegel, W.; Velde, C. Van de; Schmoll, H. J.; Sobrero, A.; Tabernero, Josep (2010)The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy ...
Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review Pentheroudakis, George; Pavlidis, Nicholas (2010)Introduction: Serous peritoneal papillary carcinoma (SPPC), though managed according to ovarian cancer therapeutic principles, has been variably considered as an ovarian cancer counterpart, a peritoneal malignancy with ...
The complex pathogenesis of bacteremia: From antimicrobial clearance mechanisms to the genetic background of the host Christaki, Eirini; Giamarellos-Bourboulis, Evangelos J. (2014)Bacteremia develops when bacteria manage to escape the host immune mechanisms or when the otherwise well-orchestrated immune response fails to control bacterial spread due to inherent or acquired immune defects that are ...